Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase‐2 study (Nord CML 006)
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
We randomised 46 newly diagnosed patients with chronic myeloid leukaemia (median age 56) to receive dasatinib 100 mg QD or imatinib 400 mg QD and report outcome as an intention‐to‐treat analysis with 36 months follow‐up. Early cytogenetic and molecular responses were superior in the dasatinib group, with a tendency that imatinib patients caught up with time. For instance, MR3.0 was reached at 3 months in 36% vs. 8% (P = 0.02), at 12 months in 81% vs. 46% (P = 0.02) and at 18 months in 73% vs. 65% (n.s.) of the patients in the two groups. In contrast, MR4.5 was consistently superior in the dasatinib group at all time points from 6 months onwards, reaching 61% vs. 21% (P < 0.05) at 36 months. Sixty‐four vs. 71% of the patients in the dasatinib and imatinib arms, respectively, remained on assigned drug. Dasatinib dose was frequently reduced, but with maintained excellent effect. One imatinib patient progressed to blastic phase, but no CML‐related deaths occurred. In conclusion, our data compare favourably with those of the dasatinib registration study, DASISION. The fast and deep molecular responses induced by dasatinib compared with imatinib may be exploited to increase the proportion of patients who can achieve a treatment‐free remission after treatment discontinuation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
La Rosée, P., Martiat, P., Leitner, A., Klag, T., Müller, M. C., Erben, P., Schenk, T., Saussele, S., & Hochhaus, A. (2013) · Annals of Hematology · doi:10.1007/s00277-013-1769-2 · Cited by 50
Cited by
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
Hochhaus, A., Baccarani, M., Silver, R. T., Schiffer, C., Apperley, J. F., Cervantes, F., Clark, R. E., Cortes, J. E., Deininger, M. W., Guilhot, F., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0776-2 · Cited by 1,547
Self-citationCortes, J. E., Saglio, G., Kantarjian, H. M., Baccarani, M., Mayer, J., Boqué, C., Shah, N. P., Chuah, C., Casanova, L., Bradley-Garelik, B., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.8899 · Cited by 947
Naqvi, K., Jabbour, E., Skinner, J., Anderson, K., Dellasala, S., Yilmaz, M., Ferrajoli, A., Bose, P., Thompson, P., Alvarado, Y., et al. (2020) · Cancer · doi:10.1002/cncr.32504 · Cited by 135
Claudiani, S., Apperley, J. F., Szydlo, R., Khan, A., Nesr, G., Hayden, C., J. Innes, A., Dominy, K., Foskett, P., Foroni, L., et al. (2021) · British Journal of Haematology · doi:10.1111/bjh.17286 · Cited by 42
Dasatinib dose management for the treatment of chronic myeloid leukemia
Talpaz, M., Saglio, G., Atallah, E., & Rousselot, P. (2018) · Cancer · doi:10.1002/cncr.31232 · Cited by 30
Metadata
- Authors
- Hjorth‐Hansen, H., Stenke, L., Söderlund, S., Dreimane, A., Ehrencrona, H., Gedde‐Dahl, T., Gjertsen, B. T., Höglund, M., Koskenvesa, P., Lotfi, K., Majeed, W., Markevärn, B., Ohm, L., Olsson‐Strömberg, U., Remes, K., Suominen, M., Simonsson, B., Porkka, K., Mustjoki, S., Richter, J., & the Nordic CML Study Group (NCMLSG)
- Venue
- European Journal of Haematology
- Publisher
- Wiley
- Published
- 2014-09-13
- Volume
- 94
- Issue
- 3
- Pages
- 243-250
- ISSN
- 0902-4441 (ISSN-L)
- 1600-0609
- OpenAlex
- W2119900325
- Cited by
- 63
- References
- 1
- FWCI
- 5.31
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase‐2 study (Nord CML 006). https://app.cochat.ai/papers/10.1111/ejh.12423
- The paper
- Hjorth‐Hansen, H., Stenke, L., Söderlund, S., Dreimane, A., Ehrencrona, H., Gedde‐Dahl, T., Gjertsen, B. T., Höglund, M., Koskenvesa, P., Lotfi, K., Majeed, W., Markevärn, B., Ohm, L., Olsson‐Strömberg, U., Remes, K., Suominen, M., Simonsson, B., Porkka, K., Mustjoki, S., . . . the Nordic CML Study Group (NCMLSG). (2015). Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase‐2 study (Nord CML 006). European Journal of Haematology. https://doi.org/10.1111/ejh.12423
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.